# Plexus Corp: Form 10-Q for the period ended Jul 2, 2022

- Company: [Plexus Corp](/companies/plxs.md) (CIK 785786)
- Form: 10-Q
- Filed: 2022-08-05
- Accepted by EDGAR: Aug 5, 2022, 12:31 ET
- Period: 2022-07-02
- Accession: 0000785786-22-000073
- Inline XBRL: yes
- Main document: https://www.sec.gov/Archives/edgar/data/785786/000078578622000073/plxs-20220702.htm
- All documents and exhibits: https://www.sec.gov/Archives/edgar/data/785786/000078578622000073/

## Figures reported in this filing

Standardized XBRL line items for the period ended 2022-07-02.

| Line item | Period | Value | XBRL concept |
| --- | --- | ---: | --- |
| Revenue | 3 months, 2022-04-03 to 2022-07-02 | $1.01bn | us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax |
| Revenue | 9 months, 2021-10-03 to 2022-07-02 | $2.77bn | us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax |
| Cost of revenue | 3 months, 2022-04-03 to 2022-07-02 | $887.7m | us-gaap:CostOfGoodsAndServicesSold |
| Cost of revenue | 9 months, 2021-10-03 to 2022-07-02 | $2.45bn | us-gaap:CostOfGoodsAndServicesSold |
| Gross profit | 3 months, 2022-04-03 to 2022-07-02 | $93.6m | us-gaap:GrossProfit |
| Gross profit | 9 months, 2021-10-03 to 2022-07-02 | $240.1m | us-gaap:GrossProfit |
| Selling, general and administrative | 3 months, 2022-04-03 to 2022-07-02 | $44.1m | us-gaap:SellingGeneralAndAdministrativeExpense |
| Selling, general and administrative | 9 months, 2021-10-03 to 2022-07-02 | $122.2m | us-gaap:SellingGeneralAndAdministrativeExpense |
| Operating income | 3 months, 2022-04-03 to 2022-07-02 | $49.6m | us-gaap:OperatingIncomeLoss |
| Operating income | 9 months, 2021-10-03 to 2022-07-02 | $115.9m | us-gaap:OperatingIncomeLoss |
| Interest expense | 3 months, 2022-04-03 to 2022-07-02 | $3.9m | us-gaap:InterestExpense |
| Interest expense | 9 months, 2021-10-03 to 2022-07-02 | $10.3m | us-gaap:InterestExpense |
| Income tax | 3 months, 2022-04-03 to 2022-07-02 | $5.8m | us-gaap:IncomeTaxExpenseBenefit |
| Income tax | 9 months, 2021-10-03 to 2022-07-02 | $13.6m | us-gaap:IncomeTaxExpenseBenefit |
| Net income | 3 months, 2022-04-03 to 2022-07-02 | $37.5m | us-gaap:NetIncomeLoss |
| Net income | 9 months, 2021-10-03 to 2022-07-02 | $87.8m | us-gaap:NetIncomeLoss |
| Diluted EPS | 3 months, 2022-04-03 to 2022-07-02 | $1.33 | us-gaap:EarningsPerShareDiluted |
| Diluted EPS | 9 months, 2021-10-03 to 2022-07-02 | $3.09 | us-gaap:EarningsPerShareDiluted |
| Basic EPS | 3 months, 2022-04-03 to 2022-07-02 | $1.35 | us-gaap:EarningsPerShareBasic |
| Basic EPS | 9 months, 2021-10-03 to 2022-07-02 | $3.14 | us-gaap:EarningsPerShareBasic |
| Diluted shares (weighted) | 3 months, 2022-04-03 to 2022-07-02 | 28,179,000 shares | us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding |
| Diluted shares (weighted) | 9 months, 2021-10-03 to 2022-07-02 | 28,452,000 shares | us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding |
| Operating cash flow | 9 months, 2021-10-03 to 2022-07-02 | −$25.8m | us-gaap:NetCashProvidedByUsedInOperatingActivities |
| Capital expenditure | 9 months, 2021-10-03 to 2022-07-02 | $85.0m | us-gaap:PaymentsToAcquirePropertyPlantAndEquipment |
| Share repurchases | 9 months, 2021-10-03 to 2022-07-02 | $46.9m | us-gaap:PaymentsForRepurchaseOfCommonStock |
| Cash and equivalents | at 2022-07-02 | $276.6m | us-gaap:CashAndCashEquivalentsAtCarryingValue |
| Current assets | at 2022-07-02 | $2.65bn | us-gaap:AssetsCurrent |
| Total assets | at 2022-07-02 | $3.20bn | us-gaap:Assets |
| Current liabilities | at 2022-07-02 | $1.86bn | us-gaap:LiabilitiesCurrent |
| Total liabilities | at 2022-07-02 | $2.15bn | us-gaap:Liabilities |
| Shareholders' equity | at 2022-07-02 | $1.06bn | us-gaap:StockholdersEquity |

## Management's discussion and analysis

As filed, 50,324 characters.

### "SAFE HARBOR" CAUTIONARY STATEMENT UNDER THE PRIVATE SECURITIES LITIGATION REFORM ACT OF 1995:

*The statements contained in this Form 10-Q that are guidance or which are not historical facts (such as statements in the future tense and statements including believe, expect, intend, plan, anticipate, goal, target and similar terms and concepts), including all discussions of periods which are not yet completed, are forward-looking statements that involve risks and uncertainties. These risks and uncertainties include the evolving effect, which may intensify, of COVID-19 on our employees, customers, suppliers, and logistics providers, including the impact of governmental actions being taken to curtail the spread of the virus. Other risks and uncertainties include, but are not limited to: the effect of inflationary pressures on our costs of production, profitability, and on the economic outlook of our markets; the effects of shortages and delays in obtaining components as a result of economic cycles, natural disasters or otherwise; the risk of customer delays, changes, cancellations or forecast inaccuracies in both ongoing and new programs; the lack of visibility of future orders, particularly in view of changing economic conditions; the economic performance of the industries, sectors and customers we serve; the effects of tariffs, trade disputes, trade agreements and other trade protection measures; the effects of the volume of revenue from certain sectors or programs on our margins in particular periods; our ability to secure new customers, maintain our current customer base and deliver product on a timely basis; the risks of concentration of work for certain customers; the particular risks relative to new or recent customers, programs or services, which risks include customer and other delays, start-up costs, potential inability to execute, the establishment of appropriate terms of agreements, and the lack of a track record of order volume and timing; the effects of start-up costs of new programs and facilities or the costs associated with the closure or consolidation of facilities; possible unexpected costs and operating disruption in transitioning programs, including transitions between Company facilities; the risk that new program wins and/or customer demand may not result in the expected revenue or profitability; the fact that customer orders may not lead to long-term relationships; our ability to manage successfully and execute a complex business model characterized by high product mix and demanding quality, regulatory, and other requirements; the risks associated with excess and obsolete inventory, including the risk that inventory purchased on behalf of our customers may not be consumed or otherwise paid for by the customer, resulting in an inventory write-off; risks related to information technology systems and data security; the ability to realize anticipated savings from restructuring or similar actions, as well as the adequacy of related charges as compared to actual expenses; increasing regulatory and compliance requirements; the effects of U.S. Tax Reform, any tax law changes as a result of change in U.S. presidential administration, and of related foreign jurisdiction tax developments; current or potential future barriers to the repatriation of funds that are currently held outside of the United States as a result of actions taken by other countries or otherwise; the potential effects of jurisdictional results on our taxes, tax rates, and our ability to use deferred tax assets and net operating losses; the weakness of areas of the global economy; the effect of changes in the pricing and margins of products; raw materials and component cost fluctuations; the potential effect of fluctuations in the value of the currencies in which we transact business; the effects of changes in economic conditions, political conditions and tax matters in the United States and in the other countries in which we do business (including as a result of the United Kingdom’s exit from the European Union); the potential effect of other world or local events or other events outside our control (such as the recent conflict between Russia and Ukraine, changes in energy prices, terrorism, global health epidemics and weather events); the impact of increased competition; an inability to successfully manage human capital; changes in financial accounting standards; and other risks detailed herein and in our other Securities and Exchange Commission filings, particularly in Risk Factors in our fiscal 2021 Form 10-K.*

### OVERVIEW

Plexus Corp. and its subsidiaries (together "Plexus," the "Company," or "we") participate in the Electronic Manufacturing Services ("EMS") industry. Since 1979, we have been partnering with companies to create the products that build a better world by providing Design and Development, Supply Chain Solutions, New Product Introduction, Manufacturing and Aftermarket Services. We are a global leader that specializes in serving customers in industries with highly complex products and demanding regulatory environments. Plexus delivers customer service excellence to leading companies by providing innovative, comprehensive solutions throughout a product’s lifecycle. We engineer innovative solutions for customers in growth markets and focus on partnering with leading global companies in the Industrial, Healthcare/Life Sciences and Aerospace/Defense market sectors. We deliver comprehensive end-to-end solutions in the Americas ("AMER"), Asia-Pacific ("APAC") and Europe, Middle East and Africa ("EMEA") regions.

The following Management's Discussion and Analysis of Financial Condition and Results of Operations ("MD&A") is intended to provide an analysis of both short-term results and future prospects from management’s perspective, including an assessment of the financial condition and results of operations, events and uncertainties that are not indicative of future operations and any other financial or statistical data that we believe will enhance the understanding of our company’s financial condition, cash flows and other changes in financial condition and results of operations.

The following information should be read in conjunction with our condensed consolidated financial statements included herein and "Risk Factors" included in Part II, Item 1A included herein as well as Part I, Item 1A of our Annual Report on Form 10-K for the fiscal year ended October 2, 2021, and our "Safe Harbor" Cautionary Statement included above.

#### Current Events Update

We continue to monitor the global outbreak and spread of COVID-19 and take steps to mitigate the potential risks to us posed by its spread and related circumstances and impacts. These efforts will continue as requirements change, new risks are identified and infections impact us. The spread and resurgence of COVID-19 from new variants in jurisdictions where we operate may make our ability to mitigate the impacts of the pandemic on our productivity more challenging.

We have experienced, and expect to continue to experience, an inability to procure certain components and materials on a timely basis due to global supply chain constraints likely as a result of the COVID-19 pandemic and worsened by geopolitical conditions including the conflict in Ukraine. These constraints have impacted our ability to meet customer demand and will continue to inhibit our ability to capture the demand from our customers. We remain in close contact with our suppliers to understand the impacts on their businesses and operations and continue to take steps to validate their ability to deliver to us on time. However, the extended lead times have required us to make additional investments in inventory to satisfy customer demand, which we expect to persist.

Over the past few quarters, global supply chain constraints have led to inflation in many of the components we acquire, as well as labor and operating costs. We expect the increase in costs to continue in the near future. Labor-related issues have become more pronounced likely as a result of COVID-19 and current economic conditions. We have been, and expect to continue to be, subject to such inflationary and general labor cost increases including in our Malaysia operations where the government has imposed a mandatory increase to the minimum wage that went into effect in our third quarter of fiscal 2022. While we have been largely able to mitigate the impacts of inflation through our contractual rights with customers on pricing, the pricing recoveries received may be dilutive to our operating margin. The inability to offset these costs in future periods or the impacts of continued inflation on end markets and our customers may affect our operating results, cash flows and inventory levels, which could increase as a result of higher component prices or the negative effects of inflation on customer end-market demand.

We believe our balance sheet is positioned to support the potential future challenges presented by COVID-19 and other macro-economic pressures we are facing. As of the third quarter of fiscal 2022, cash and cash equivalents and restricted cash were $278 million, while debt, finance lease obligations and other financing were $435 million. To further ensure our ability to meet the needs of working capital investments to support anticipated revenue growth, we refinanced our revolving credit facility, expanding the maximum commitment from $350.0 million to $500.0 million. Borrowings under our Credit Facility as of July 2, 2022 were $240 million, leaving $260 million of our revolving commitment of $500.0 million available for use as of July 2, 2022 as well as the ability to expand our revolving commitment to $750 million upon mutual agreement with the bank. Refer to Note 3, "Debt, Finance Lease Obligations and Other Financing," in Notes to Condensed Consolidated Financial Statements and "Management’s Discussion and Analysis Liquidity and Capital Resources" in Part I, Item 2 for further information.

The recent conflict between Russia and Ukraine has negatively impacted the global economy and led to various economic sanctions being imposed by the U.S., United Kingdom, European Union and other countries against Russia. While the impacts of the conflict have not been material on our operating results, as we do not have operations or material customers or suppliers in either country, it is not possible to predict the broader consequences of this conflict.

See in particular the "Risk Factors" contained in our Annual Report on Form 10-K for the fiscal year ended October 2, 2021, including *"Our financial condition and results of operations may be materially adversely affected by the ongoing coronavirus (COVID-19) outbreak", "We experience component shortages, price fluctuations and supplier quality concerns.", and "Plexus is a multinational corporation and operating in multiple countries exposes us to increased risks, including adverse local developments and currency risks."*

### RESULTS OF OPERATIONS

***Consolidated Performance Summary.*** The following table presents selected consolidated financial data (dollars in millions, except per share data):

|  | Three Months Ended July 2, 2022 | July 3, 2021 | Nine Months Ended July 2, 2022 | July 3, 2021 |
| --- | ---: | ---: | ---: | ---: |
| Net sales | $981.3 | $814.4 | $2,687.5 | $2,525.6 |
| Cost of sales | 887.7 | 740.3 | 2,447.4 | 2,281.3 |
| Gross profit | 93.6 | 74.1 | 240.1 | 244.3 |
| Gross margin | 9.5% | 9.1% | 8.9% | 9.7% |
| Operating income | 49.6 | 36.4 | 115.9 | 133.9 |
| Operating margin | 5.1% | 4.5% | 4.3% | 5.3% |
| Other expense | 6.3 | 3.5 | 14.5 | 12.9 |
| Income tax expense | 5.8 | 5.3 | 13.6 | 15.4 |
| Net income | 37.5 | 27.6 | 87.8 | 105.6 |
| Diluted earnings per share | $1.33 | $0.95 | $3.09 | $3.60 |
| Return on invested capital\* |  |  | 11.5% | 15.9% |
| Economic return\* |  |  | 2.2% | 7.8% |
| \*Non-GAAP metric; refer to "Return on Invested Capital ("ROIC") and economic return" below for more information and Exhibit 99.1 to this Quarterly Report on Form 10-Q for a reconciliation. |  |  |  |  |

***Net sales.*** For the three months ended July 2, 2022, net sales increased $166.9 million, or 20.5%, as compared to the three months ended July 3, 2021. For the nine months ended July 2, 2022, net sales increased $161.9 million, or 6.4%, as compared to the nine months ended July 3, 2021.

Net sales are analyzed by management by geographic segment, which reflects our reportable segments, and by market sector. Management measures operational performance and allocates resources on a geographic segment basis. Our global business development strategy is based on our targeted market sectors.

A discussion of net sales by reportable segment is presented below (in millions):

| Net sales: | Three Months Ended July 2, 2022 | July 3, 2021 | Nine Months Ended July 2, 2022 | July 3, 2021 |
| --- | ---: | ---: | ---: | ---: |
| AMER | $342.6 | $318.9 | $931.1 | $1,011.2 |
| APAC | 586.3 | 446.9 | 1,611.9 | 1,357.1 |
| EMEA | 84.2 | 76.5 | 230.7 | 238.5 |
| Elimination of inter-segment sales | (31.8) | (27.9) | (86.2) | (81.2) |
| Total net sales | $981.3 | $814.4 | $2,687.5 | $2,525.6 |

***AMER.*** Net sales for the three months ended July 2, 2022 in the AMER segment increased $23.7 million, or 7.4%, as compared to the three months ended July 3, 2021. The increase in net sales was driven by a $26.8 million increase in production ramps of new products for existing customers, overall net increased customer end-market demand and increased pricing associated with inflated component prices, partially offset by the impact of supply chain constraints that have created limitations with meeting available customer demand. These increases were further offset by an $8.3 million decrease due to partial loss of business with customers and a $6.4 million decrease for end-of-life products.

During the nine months ended July 2, 2022, net sales in the AMER segment decreased $80.1 million, or 7.9%, as compared to the nine months ended July 3, 2021. The decrease in net sales was driven by a $55.5 million decrease for end-of-life products, a $39.0 million decrease due to partial loss of business with customers, $3.6 million due to a disengagement with a customer and supply chain constraints that have created limitations with meeting available customer demand. These decreases were partially offset by a $34.0 million increase in production ramps of new products for existing customers, overall net increased customer end-market demand and increased pricing associated with inflated component prices as well as a $5.0 million increase in production ramps for a new customer.

***APAC.*** Net sales for the three months ended July 2, 2022 in the APAC segment increased $139.4 million, or 31.2%, as compared to the three months ended July 3, 2021. The increase in net sales was driven by overall net increased customer end-market demand and increased pricing associated with inflated component prices, a $25.0 million increase in production ramps of new products for existing customers and partial recovery from supply chain constraints that had previously created limitations with meeting available customer demand.

During the nine months ended July 2, 2022, net sales in the APAC segment increased $254.8 million, or 18.8%, as compared to the nine months ended July 3, 2021. The increase in net sales was driven by overall net increased customer end-market demand and increased pricing associated with inflated component prices as well as a $68.4 million increase in production ramps of new products for existing customers, partially offset by the impact of supply chain constraints that have created limitations with meeting available customer demand. These increases were further offset by a $31.9 million decrease for end-of-life products and a $5.4 million decrease for the loss of existing business.

***EMEA.*** Net sales for the three months ended July 2, 2022 in the EMEA segment increased $7.7 million, or 10.1%, as compared to the three months ended July 3, 2021. The increase in net sales was driven by overall net increased customer end-market demand and increased pricing associated with inflated component prices.

During the nine months ended July 2, 2022, net sales in the EMEA segment decreased $7.8 million, or 3.3%, as compared to the nine months ended July 3, 2021. The decrease in net sales was driven by overall net decreased customer end-market demand, partially offset by a $6.7 million increase in production ramps of new products for existing customers.

Our net sales by market sector were as follows (in millions):

| Net sales: | Three Months Ended July 2, 2022 | July 3, 2021 | Nine Months Ended July 2, 2022 | July 3, 2021 |
| --- | ---: | ---: | ---: | ---: |
| Industrial | $454.4 | $371.9 | $1,232.9 | $1,156.9 |
| Healthcare/Life Sciences | 400.8 | 324.5 | 1,098.5 | 993.5 |
| Aerospace/Defense | 126.1 | 118.0 | 356.1 | 375.2 |
| Total net sales | $981.3 | $814.4 | $2,687.5 | $2,525.6 |

***Industrial.*** Net sales for the three months ended July 2, 2022 in the Industrial sector increased $82.5 million, or 22.2%, as compared to the three months ended July 3, 2021. The increase in net sales was driven by overall net increased customer end-market demand and increased pricing associated with inflated component prices as well as a $16.6 million increase in production ramps of new products for existing customers, partially offset by the impact of supply chain constraints that have created limitations with meeting available customer demand. The increase was further offset by a $9.1 million decrease due to partial loss of business with customers.

During the nine months ended July 2, 2022, net sales in the Industrial sector increased $76.0 million, or 6.6%, as compared to the nine months ended July 3, 2021. The increase in net sales was driven by overall net increased customer end-market demand and increased pricing associated with inflated component prices as well as a $26.5 million increase due to production ramps of new products for existing customers, partially offset by the impact of supply chain constraints that have created limitations with meeting available customer demand. The increase was further offset by a $39.3 million decrease due to partial loss of business with customers, $3.6 million due to a disengagement with a customer and an $18.2 million decrease for end-of-life products.

***Healthcare/Life Sciences.*** Net sales for the three months ended July 2, 2022 in the Healthcare/Life Sciences sector increased $76.3 million, or 23.5%, as compared to the three months ended July 3, 2021. The increase in net sales was driven by overall net increased customer end-market demand and increased pricing associated with inflated component prices, a $31.8 million increase due to production ramps of new products for existing customers and a partial recovery of supply chain constraints that had previously created limitations with meeting available customer demand. These increases were partially offset by a $6.2 million decrease for end-of-life products.

During the nine months ended July 2, 2022, net sales in the Healthcare/Life Sciences sector increased $105.0 million, or 10.6%, as compared to the nine months ended July 3, 2021. The increase in net sales was driven by overall net increased customer end-market demand and increased pricing associated with inflated component prices, a $59.8 million increase due to production ramps of new products for existing customers and a partial recovery of supply chain constraints that had previously created limitations with meeting available customer demand. These increases were partially offset by a $65.0 million decrease for end-of-life products and a $5.4 million decrease for the loss of existing business.

***Aerospace/Defense.*** Net sales for the three months ended July 2, 2022 in the Aerospace/Defense sector increased $8.1 million, or 6.9%, as compared to the three months ended July 3, 2021. The increase was driven by a $7.0 million increase due to production ramps of new products for existing customers as well as overall net increased customer end-market demand.

During the nine months ended July 2, 2022, net sales in the Aerospace/Defense sector decreased $19.1 million, or 5.1%, as compared to the nine months ended July 3, 2021. The decrease was driven by net decreased customer end-market demand, inclusive of the impact of supply chain constraints that have created limitations with meeting available customer demand and a $6.0 million decrease due to end-of-life products. These decreases were partially offset by a $22.4 million increase due to production ramps of new products for existing customers.

***Cost of sales.*** Cost of sales for the three months ended July 2, 2022 increased $147.4 million, or 19.9%, as compared to the three months ended July 3, 2021, while cost of sales for the nine months ended July 2, 2022 increased $166.1 million, or 7.3%, as compared to the nine months ended July 3, 2021. Cost of sales is comprised primarily of material and component costs, labor costs and overhead. For the three and nine months ended July 2, 2022 and the three and nine months ended July 3, 2021, approximately 89% to 90% of the total cost of sales was variable in nature and fluctuated with sales volumes. Of these amounts, approximately 87% to 88% of the variable costs for the three and nine months ended July 2, 2022 and July 3, 2021, were related to material and component costs.

As compared to the three and nine months ended July 3, 2021, the increase in cost of sales for the three and nine months ended July 2, 2022 was primarily driven by the increase in net sales, unfavorable customer mix, an increase in fixed costs, reduced labor productivity and increased labor costs.

***Gross profit.*** Gross profit for the three months ended July 2, 2022 increased $19.5 million, or 26.3%, as compared to the three months ended July 3, 2021. Gross margin of 9.5% for the three months ended July 2, 2022 increased 40 basis points compared to the three months ended July 3, 2021. The primary driver of the increase in gross profit and gross margin for the three months ended July 2, 2022 was the increase in net sales and reduced employee compensation and supplies costs associated with COVID-19, partially offset by unfavorable customer mix, increased fixed costs, reduced labor productivity and increased labor costs.

Gross profit for the nine months ended July 2, 2022 decreased $4.2 million, or 1.7%, as compared to the nine months ended July 3, 2021. Gross margin of 8.9% for the nine months ended July 2, 2022 decreased 80 basis points compared to the nine months ended July 3, 2021. The primary driver of the decrease in gross profit and gross margin for the nine months ended July 2, 2022 was unfavorable customer mix, an increase in fixed costs, reduced labor productivity and increased labor costs, partially offset by the increase in net sales and reduced employee compensation and supplies costs associated with COVID-19.

***Operating income.*** Operating income for the three months ended July 2, 2022 increased $13.2 million, or 36.3%, as compared to the three months ended July 3, 2021. Operating margin of 5.1% for the three months ended July 2, 2022 increased 60 basis points compared to the three months ended July 3, 2021. The primary driver of the increase in operating income and operating margin for the three months ended July 2, 2022 was the result of the increase in gross profit and gross margin along with a $1.2 million decrease in restructuring and impairment charges, partially offset by a $6.4.million increase in selling and administrative expenses ("S&A"). The increase in S&A was primarily due to an increase in compensation costs.

Operating income for the nine months ended July 2, 2022 decreased $18.0 million, or 13.4%, as compared to the nine months ended July 3, 2021. Operating margin of 4.3% for the nine months ended July 2, 2022 decreased 100 basis points compared to the nine months ended July 3, 2021. The primary driver of the decrease in operating income and operating margin for the nine months ended July 2, 2022 was the result of the decrease in gross profit and gross margin along with a $13.8 million increase in S&A. The increase in S&A was primarily due to an increase in bad debt expense compared to recovery of a previously reserved customer receivable received during the nine months ended July 3, 2021, as well as increased compensation costs.

A discussion of operating income by reportable segment is presented below (in millions):

| Operating income (loss): | Three Months Ended July 2, 2022 | July 3, 2021 | Nine Months Ended July 2, 2022 | July 3, 2021 |
| --- | ---: | ---: | ---: | ---: |
| AMER | $17.0 | $9.2 | $26.5 | $51.9 |
| APAC | 67.3 | 57.1 | 188.8 | 176.7 |
| EMEA | 2.6 | 0.1 | 4.0 | (2.5) |
| Corporate and other costs | (37.3) | (30.0) | (103.4) | (92.2) |
| Total operating income | $49.6 | $36.4 | $115.9 | $133.9 |

***AMER.*** Operating income increased $7.8 million for the three months ended July 2, 2022 as compared to the three months ended July 3, 2021, primarily as a result of an increase in net sales and a positive shift in customer mix, partially offset by increased fixed costs and increased labor costs.

During the nine months ended July 2, 2022, operating income in the AMER segment decreased $25.4 million as compared to the nine months ended July 3, 2021, primarily as a result of a decrease in net sales, increased fixed costs, reductions in labor productivity and increased labor costs. There was also an increase in bad debt expense compared to recovery of a previously reserved customer receivable for the nine months ended July 3, 2021. This was partially offset by a positive shift in customer mix.

***APAC.*** Operating income increased $10.2 million for the three months ended July 2, 2022 as compared to the three months ended July 3, 2021, primarily as a result of an increase in net sales and improvements in labor productivity, partially offset by a negative shift in customer mix and increased fixed costs.

During the nine months ended July 2, 2022, operating income in the APAC segment increased $12.1 million as compared to the nine months ended July 3, 2021, primarily as a result of an increase in net sales, partially offset by a negative shift in customer mix, increased fixed costs, reductions in labor productivity and increased labor costs.

***EMEA.*** Operating income increased $2.5 million for the three months ended July 2, 2022 as compared to the three months ended July 3, 2021 primarily as a result of an increase in net sales, a positive shift in customer mix and improvements in labor productivity.

During the nine months ended July 2, 2022, operating income in the EMEA segment increased $6.5 million as compared to the nine months ended July 3, 2021, primarily as a result of a positive shift in customer mix and improvements in labor productivity, partially offset by a decrease in net sales.

***Other expense.*** Other expense for the three months ended July 2, 2022 increased $2.8 million as compared to the three months ended July 3, 2021. The increase in other expense was primarily due to an increase in foreign exchange losses of $1.2 million, an increase in factoring fees of $0.8 million and an increase in interest expense of $0.7 million.

Other expense for the nine months ended July 2, 2022 increased $1.6 million as compared to the nine months ended July 3, 2021. The increase in other expense was primarily due to an increase in foreign exchange losses of $1.0 million, an increase in factoring fees of $0.9 million, partially offset by a decrease in interest expense of $0.8 million.

***Income taxes.*** Income tax expense for the three and nine months ended July 2, 2022 was $5.8 million and $13.6 million, respectively, compared to $5.3 million and $15.4 million for the three and nine months ended July 3, 2021, respectively. The increase for the three months ended July 2, 2022 as compared to July 3, 2021 was primarily due to an increase in pre-tax book income and an increase in discrete tax expenses of $1.4 million, partially offset by the change in the geographic distribution of pre-tax book income. The decrease for the nine months ended July 2, 2022 as compared to July 3, 2021 was primarily due to a decrease in pre-tax book income and change in geographic distribution of pre-tax book income, partially offset by an increase in discrete tax expenses of $2.0 million.

Our annual effective tax rate varies from the U.S. statutory rate of 21.0% primarily due to the geographic distribution of worldwide earnings as well as a tax holiday granted to a subsidiary located in the APAC segment where we derive a significant portion of our earnings. Our effective tax rate may also be impacted by disputes with taxing authorities, tax planning activities, adjustments to uncertain tax positions and changes in valuation allowances.

The annual effective tax rate for fiscal 2022 is expected to be approximately 13.0% to 15.0% assuming no changes to tax laws.

***Net Income.*** Net income for the three months ended July 2, 2022 increased $9.9 million, or 35.9%, from the three months ended July 3, 2021 to $37.5 million. Net income increased primarily as a result of the increase in operating income, as previously discussed.

Net income for the nine months ended July 2, 2022 decreased $17.8 million, or 16.9%, from the nine months ended July 3, 2021 to $87.8 million. Net income decreased primarily as a result of the decrease in operating income, partially offset by the decrease in tax expense, as previously discussed.

***Diluted earnings per share.*** Diluted earnings per share increased to $1.33 for the three months ended July 2, 2022 from $0.95 for the three months ended July 3, 2021 primarily as a result of increased net income due to the factors previously discussed and a reduction in diluted shares outstanding due to repurchase activity under our share repurchase plans.

Diluted earnings per share decreased to $3.09 for the nine months ended July 2, 2022 from $3.60 for the nine months ended July 3, 2021 primarily as a result of decreased net income due to the factors previously discussed, partially offset by a reduction in diluted shares outstanding due to repurchase activity under our share repurchase plans.

***Return on Invested Capital ("ROIC") and economic return.*** We use a financial model that is aligned with our business strategy and includes a ROIC goal of 15%.

Non-GAAP financial measures, including ROIC and economic return, are used for internal management goals and decision making because such measures provide management and investors additional insight into financial performance. In particular, we provide ROIC and economic return because we believe they offer insight into the metrics that are driving management decisions because we view ROIC and economic return as important measures in evaluating the efficiency and effectiveness of our long-term capital requirements. We also use ROIC as a performance criteria in determining certain elements of compensation and certain compensation incentives are based on economic return performance.

We define ROIC as tax-effected operating income before restructuring and other special items divided by average invested capital over a rolling four-quarter period for the third quarter. Invested capital is defined as equity plus debt and operating lease liabilities, less cash and cash equivalents. Other companies may not define or calculate ROIC in the same way. ROIC and other non-GAAP financial measures should be considered in addition to, not as a substitute for, measures of our financial performance prepared in accordance with U.S. generally accepted accounting principles ("GAAP"). We define economic return as ROIC less our weighted average cost of capital ("WACC").

We review our internal calculation of WACC annually. Our WACC is 9.3% for fiscal 2022 as compared to 8.1% for fiscal 2021. By exercising discipline to generate ROIC in excess of our WACC, our goal is to create value for our shareholders. For the nine months ended July 2, 2022, ROIC of 11.5% reflects an economic return of 2.2%, based on our weighted average cost of capital of 9.3%. For the nine months ended July 3, 2021, ROIC of 15.9% reflects an economic return of 7.8%, based on our weighted average cost of capital of 8.1% for that fiscal year.

For a reconciliation of ROIC, economic return and adjusted operating income (tax effected) to our financial statements that were prepared using GAAP, see Exhibit 99.1 to this quarterly report on Form 10-Q, which exhibit is incorporated herein by reference.

Refer to the table below, which includes the calculation of ROIC and economic return for the indicated fiscal period (dollars in millions):

|  | Nine Months Ended July 2, 2022 | July 3, 2021 |
| --- | ---: | ---: |
| Adjusted operating income (tax effected) | $135.2 | $159.1 |
| Average invested capital | 1,178.1 | 1,003.6 |
| After-tax ROIC | 11.5% | 15.9% |
| WACC | 9.3% | 8.1% |
| Economic return | 2.2% | 7.8% |

27

### LIQUIDITY AND CAPITAL RESOURCES

Cash and cash equivalents and restricted cash were $277.8 million as of July 2, 2022, as compared to $270.5 million as of October 2, 2021.

As of July 2, 2022, 94% of our cash and cash equivalents balance was held outside of the U.S. by our foreign subsidiaries. Currently, we believe that our cash balance, together with cash available under our Credit Facility, will be sufficient to meet our liquidity needs and potential share repurchases, if any, for the next twelve months and for the foreseeable future.

Our future cash flows from operating activities will be reduced by $47.7 million due to cash payments for U.S. federal taxes on the deemed repatriation of undistributed foreign earnings that are payable over an eight year period that began in fiscal 2019 with the first payment. The table below provides the expected timing of these future cash outflows, in accordance with the following installment schedule for the remaining years (in millions):

|  |  |
| --- | ---: |
| 2023 | $5.5 |
| 2024 | 10.6 |
| 2025 | 14.2 |
| 2026 | 17.4 |
| Total | $47.7 |

***Cash Flows.*** The following table provides a summary of cash flows (in millions):

|  | Nine Months Ended July 2, 2022 | July 3, 2021 |
| --- | ---: | ---: |
| Cash (used in) provided by operating activities | $(25.8) | $131.5 |
| Cash used in investing activities | (85.1) | (34.3) |
| Cash provided by (used in) financing activities | 122.1 | (179.1) |

***Operating Activities.*** Cash flows used in operating activities were $25.8 million for the nine months ended July 2, 2022, as compared to cash flows provided by operating activities of $131.5 million for the nine months ended July 3, 2021. The decrease was primarily due to cash flow (reductions) improvements of:

- $(17.8) million decrease in net income.
- $(494.5) million in inventory cash flows primarily attributable to efforts to mitigate supply chain constraints for certain components with longer lead times by acquiring materials to support production of certain products in future quarters. This allows us to support our customers' continuity of supply for their customers. Supply chain constraints have also led to inflation in many of the components we acquire, increasing inventory. In addition, inventory levels have increased to support the ramp of customer programs.
- $(119.0) million in accounts receivable cash flows driven by increased net sales as well as timing of customer shipments and payments.
- $166.2 million in accounts payables cash flows driven by increased purchasing activity to support the ramp of customer programs as well as supply chain constraints leading to inflation in many of the components we acquire.
- $170.2 million in customer deposit cash flows driven by significant deposits received from ten customers in the current year to cover certain inventory balances associated with longer lead times as a result of supply chain constraints.
- $131.7 million in other current and non-current liabilities cash flows driven by an increase in advance payments from customers.

The following table provides a summary of cash cycle days for the periods indicated (in days):

|  | Three Months Ended July 2, 2022 | July 3, 2021 |
| --- | ---: | ---: |
| Days in accounts receivable | 57 | 52 |
| Days in contract assets | 12 | 13 |
| Days in inventory | 160 | 108 |
| Days in accounts payable | (87) | (71) |
| Days in cash deposits | (40) | (22) |
| Annualized cash cycle | 102 | 80 |

We calculate days in accounts receivable and contract assets as each balance sheet item for the respective quarter divided by annualized sales for the respective quarter by day. We calculate days in inventory, accounts payable and cash deposits as each balance sheet line item for the respective quarter divided by annualized cost of sales for the respective quarter by day. We calculate annualized cash cycle as the sum of days in accounts receivable, days in contract assets and days in inventory, less days in accounts payable and days in cash deposits.

As of July 2, 2022, annualized cash cycle days increased 22 days compared to July 3, 2021 due to the following:

Days in accounts receivable for the three months ended July 2, 2022 increased five days compared to the three months ended July 3, 2021. The increase is primarily attributable to the timing of customer shipments and payments and mix of customer payment terms, partially offset by an increase in factored receivables.

Days in contract assets for the three months ended July 2, 2022 decreased one day compared to the three months ended July 3, 2021. The decrease is primarily attributable to increased net sales.

Days in inventory for the three months ended July 2, 2022 increased 52 days compared to the three months ended July 3, 2021. The increase is primarily attributable to efforts to mitigate supply chain constraints for certain components with longer lead times by acquiring materials to support production of certain products in future quarters. This allows us to support our customers' continuity of supply for their customers. Supply chain constraints have also led to inflation in many of the components we acquire, increasing inventory. In addition, inventory levels have increased to support the ramp of customer programs.

Days in accounts payable for the three months ended July 2, 2022 increased 16 days compared to the three months ended July 3, 2021. The increase is primarily attributable to increased purchasing activity to support the ramp of customer products as well as supply chain constraints leading to inflation in many of the components we acquire.

Days in cash deposits for the three months ended July 2, 2022 increased 18 days compared to the three months ended July 3, 2021. The increase was primarily attributable to significant deposits received from nine customers to cover certain inventory balances.

***Free Cash Flow.*** We define free cash flow ("FCF"), a non-GAAP financial measure, as cash flow (used in) provided by operations less capital expenditures. FCF was $(110.8) million for the nine months ended July 2, 2022 compared to $97.1 million for the nine months ended July 3, 2021, a decrease of $207.9 million.

Non-GAAP financial measures, including FCF, are used for internal management assessments because such measures provide additional insight to investors into ongoing financial performance. In particular, we provide FCF because we believe it offers insight into the metrics that are driving management decisions. We view FCF as an important financial metric as it demonstrates our ability to generate cash and can allow us to pursue opportunities that enhance shareholder value. FCF is a non-GAAP financial measure that should be considered in addition to, not as a substitute for, measures of our financial performance prepared in accordance with GAAP.

A reconciliation of FCF to our financial statements that were prepared using GAAP follows (in millions):

|  | Nine Months Ended July 2, 2022 | July 3, 2021 |
| --- | ---: | ---: |
| Cash flows (used in) provided by operating activities | $(25.8) | $131.5 |
| Payments for property, plant and equipment | (85.0) | (34.4) |
| Free cash flow | $(110.8) | $97.1 |

***Investing Activities.*** Cash flows used in investing activities were $85.1 million for the nine months ended July 2, 2022 compared to $34.3 million for the nine months ended July 3, 2021. The increase in cash used in investing activities was due to a $50.6 million increase in capital expenditures, primarily due to our manufacturing footprint expansion in Bangkok, Thailand.

We estimate funded capital expenditures for fiscal 2022 will be approximately $110.0 million to $120. 0 million, of which $85.0 million was utilized through the first nine months of fiscal 2022. The remaining fiscal 2022 capital expenditures are anticipated to be used primarily for our manufacturing footprint expansion in Bangkok, Thailand, and to support new program ramps and replace older equipment.

***Financing Activities.*** Cash flows provided by financing activities were $122.1 million for the nine months ended July 2, 2022 compared to cash flows used in financing activities of $179.1 million for the nine months ended July 3, 2021. The increase was primarily attributable to an increase of $273.0 million in net borrowings on the Credit Facility and a decrease of $32.3 million in cash used to repurchase our common stock.

On August 20, 2019, the Board of Directors approved a share repurchase program under which we were authorized to repurchase $50.0 million of our common stock (the "2019 Program"). During the nine months ended July 3, 2021, we completed the 2019 Program by repurchasing 73,560 shares under this program for $5.3 million at an average price of $72.44 per share.

On August 13, 2020, the Board of Directors approved a share repurchase program under which we were authorized to repurchase up to $50.0 million of our common stock (the "2021 Program"). On November 18, 2020, the Board of Directors approved an additional $50.0 million in share repurchase authority under the existing 2021 Program such that there then existed a total of $100.0 million in share repurchase authority under the program. The 2021 program commenced upon completion of the 2019 Program. During the three months ended July 3, 2021, we repurchased 291,898 shares under this program for $27.3 million at an average price of $93.53 per share. During the nine months ended July 3, 2021, the Company repurchased 874,706 shares under this program for $73.9 million at an average price of $84.45 per share.

On August 11, 2021, the Board of Directors approved a share repurchase program under which we were authorized to repurchase up to $50.0 million of its common stock (the "2022 Program"). The 2022 Program commenced upon completion of the 2021 Program. The 2022 Program has no expiration. During the three months ended July 2, 2022, we repurchased 148,571 shares under this program for $11.7 million at an average price of $79.27 per share. During the nine months ended July 2, 2022, we repurchased 564,718 shares under this program for $46.9 million at an average price of $83.07 per share. As of July 2, 2022, we completed the 2022 Program, and there is no remaining authority for share repurchases.

All shares repurchased under the aforementioned programs were recorded as treasury stock.

On June 15, 2018, we entered into a Note Purchase Agreement (the “2018 NPA”) pursuant to which we issued an aggregate of $150.0 million in principal amount of unsecured senior notes, consisting of $100.0 million in principal amount 4.05% Series A Senior Notes, due on June 15, 2025, and $50.0 million in principal amount of 4.22% Series B Senior Notes, due on June 15, 2028 (collectively, the “2018 Notes”), in a private placement. The 2018 NPA includes customary operational and financial covenants with which we are required to comply, including, among others, maintenance of certain financial ratios such as a total leverage ratio and a minimum interest coverage ratio. The 2018 Notes may be prepaid in whole or in part at any time, subject to payment of a make-whole amount; interest on the 2018 Notes is payable semiannually. As of July 2, 2022, we were in compliance with the covenants under the 2018 NPA.

On June 9, 2022, we refinanced our then-existing senior unsecured revolving credit facility (as amended by that certain Amendment No. 1 to Credit Agreement dated April 29, 2020, the "Prior Credit Facility") by entering into a new five-year revolving credit facility (collectively with the Prior Credit Facility, referred to as the "Credit Facility"), which expanded the maximum commitment from $350.0 million to $500.0 million and extended the maturity from May 15, 2024 to June 9, 2027. The maximum commitment under the Credit Facility may be further increased to $750.0 million, generally by mutual agreement of the lenders and us, subject to certain customary conditions. During the nine months ended July 2, 2022, the highest daily borrowing was $327.0 million; the average daily borrowings were $204.9 million. We borrowed $524.0 million and repaid $339.0 million of revolving borrowings under the Credit Facility during the nine months ended July 2, 2022. As of July 2, 2022, we were in compliance with all financial covenants relating to the Credit Facility, which are generally consistent with those in the 2018 NPA discussed above. We are required to pay a commitment fee on the daily Credit Facility based on our leverage ratio; the fee was 0.15% as of July 2, 2022.

The Credit Facility and the 2018 NPA allow for the future payment of cash dividends or the repurchase of shares provided that no event of default (including any failure to comply with a financial covenant) exists at the time of, or would be caused by, the dividend payment or the share repurchases. We have not paid cash dividends in the past. However, we evaluate from time to time potential uses of excess cash, which in the future may include share repurchases above those already authorized, a special dividend or recurring dividends.

We have Master Accounts Receivable Purchase Agreements with MUFG Bank, New York Branch (formerly known as The Bank of Tokyo-Mitsubishi UFJ, Ltd.) (the "MUFG RPA"), HSBC Bank (China) Company Limited, Xiamen branch (the "HSBC RPA") and other unaffiliated financial institutions, under which we may elect to sell receivables, at a discount, on an ongoing basis. These facilities are uncommitted facilities. The maximum facility amount under the MUFG RPA as of July 2, 2022 is $340.0 million. The maximum facility amount under the HSBC RPA as of July 2, 2022 is $60.0 million. The MUFG RPA will be automatically extended each year unless any party gives no less than 10 days prior notice that the agreement should not be extended. The terms of the HSBC RPA are generally consistent with the terms of the MUFG RPA previously discussed.

We sold $213.6 million and $180.6 million of trade accounts receivable under these programs during the three months ended July 2, 2022 and July 3, 2021, respectively, in exchange for cash proceeds of $212.3 million and $180.1 million, respectively.

We sold $563.8 million and $574.6 million of trade accounts receivable under these programs during the nine months ended July 2, 2022 and July 3, 2021, respectively, in exchange for cash proceeds of $561.3 million and $573.0 million, respectively.

As of July 2, 2022 and October 2, 2021, $216.9 million and $176.0 million, respectively, of accounts receivables sold under trade accounts receivable programs and subject to servicing by us remained outstanding and had not yet been collected.

In all cases, the sale discount was recorded within "Miscellaneous, net" in the Condensed Consolidated Statements of Comprehensive Income in the period of the sale. For further information regarding the receivable sale programs, see Note 13, "Trade Accounts Receivable Sale Programs," in Notes to Condensed Consolidated Financial Statements.

Based on current expectations, we believe that our projected cash flows provided by operations, available cash and cash equivalents, potential borrowings under the Credit Facility and our leasing capabilities should be sufficient to meet our working capital and fixed capital requirements, as well as execution upon our share repurchase authorizations as management deems appropriate, for the next twelve months. We believe our balance sheet is positioned to support the potential future challenges presented by COVID-19 and other macro-economic factors, including increased working capital requirements associated with longer lead time for components, increased component and labor costs, and operating inefficiencies due to supply chain constraints or workplace safety restrictions. As of the end of the third quarter of fiscal 2022, cash and cash equivalents and restricted cash were $278 million, while debt, finance lease obligations and other financing were $435 million. To further ensure our ability to meet the needs of working capital investments to support anticipated revenue growth, we refinanced our credit facility, expanding the maximum commitment from $350.0 million to $500.0 million, as discussed above. If our future financing needs increase, then we may need to arrange additional debt or equity financing. Accordingly, we evaluate and consider from time to time various financing alternatives to supplement our financial resources. However, we cannot be assured that we will be able to make any such arrangements on acceptable terms or at all.

### DISCLOSURE ABOUT CRITICAL ACCOUNTING ESTIMATES

Our critical accounting estimates are disclosed in our 2021 Annual Report on Form 10-K. During the third quarter of fiscal 2022, there were no material changes.

### NEW ACCOUNTING PRONOUNCEMENTS

See Note 1, "Basis of Presentation," in Notes to Condensed Consolidated Financial Statements regarding recent accounting pronouncements.

## Market risk

As filed, 3,837 characters.

We are exposed to market risk from changes in foreign exchange and interest rates. We selectively use financial instruments to reduce such risks. We do not use derivative financial instruments for speculative purposes.

### Foreign Currency Risk

Our international operations create potential foreign exchange risk. Our policy is to selectively hedge our foreign currency denominated transactions in a manner that partially offsets the effects of changes in foreign currency exchange rates. We typically use foreign currency contracts to hedge only those currency exposures associated with certain assets and liabilities denominated in non-functional currencies. Corresponding gains and losses on the underlying transaction generally offset the gains and losses on these foreign currency hedges. We cannot predict changes in currency rates, nor the degree to which we will be able to manage the impacts of currency exchange rate changes. Such changes could have a material effect on our business, results of operations and financial condition.

Our percentages of transactions denominated in currencies other than the U.S. dollar for the indicated periods were as follows:

|  | Three Months Ended July 2, 2022 | July 3, 2021 |
| --- | ---: | ---: |
| Net Sales | 9% | 10% |
| Total Costs | 15% | 16% |

We have evaluated the potential foreign currency exchange rate risk on transactions denominated in currencies other than the U.S. dollar for the periods presented above. Based on our overall currency exposure, as of July 2, 2022, a 10.0% change in the value of the U.S. dollar relative to our other transactional currencies would not have a material effect on our financial position, results of operations, or cash flows.

### Interest Rate Risk

We have financial instruments, including cash equivalents and debt, which are sensitive to changes in interest rates. The primary objective of our investment activities is to preserve principal, while maximizing yields without significantly increasing market risk. To achieve this, we limit the amount of principal exposure to any one issuer. We cannot predict changes in interest rates.

As of July 2, 2022, our only material interest rate risk was associated with our Credit Facility. Borrowings under the Credit Facility bear interest, at the Company's option, at (a)(1) for borrowings denominated in U.S. dollars, the Term Secured Overnight Financing Rate ("SOFR"), (2) for borrowings denominated in pounds sterling, the Daily Simple Risk-Free Rate, plus, in each case of (a)(1) and (2), 10 basis points, (b) for borrowings denominated in euros, the EURIBOR Rate plus a statutory reserve rate, or (c) an Alternate Base Rate equal to the highest of (i) 100 basis points per annum, (ii) the prime rate last quoted by The Wall Street Journal (or, if not quoted, as otherwise provided in the Credit Facility), (iii) the greater of the federal funds effective rate and the overnight bank funding rate in effect on such day plus, in each case, 50 basis points per annum (or, if neither are available, as otherwise provided in the Credit Facility), and (iv) Term SOFR for a one month interest period on such day plus 110 basis points, plus, in each case of (a), (b), and (c), an applicable interest rate margin based on the Company's then current consolidated total indebtedness (minus certain unrestricted cash and cash equivalents in an amount not to exceed $100 million) to consolidated EBITDA. As of July 2, 2022, the borrowing rate under the Credit Facility was SOFR plus 1.10%. Borrowings under the 2018 NPA are based on a fixed interest rate, thus mitigating much of our interest rate risk. Based on our overall interest rate exposure, as of July 2, 2022, a 10.0% change in interest rates would not have a material effect on our financial position, results of operations, or cash flows.

## Controls and procedures

As filed, 1,670 characters.

### Disclosure Controls and Procedures

The Company maintains disclosure controls and procedures designed to ensure that the information the Company must disclose in its filings with the Securities and Exchange Commission ("SEC") is recorded, processed, summarized and reported on a timely basis. The Company’s Chief Executive Officer ("CEO") and Chief Financial Officer ("CFO") have reviewed and evaluated, with the participation of the Company’s management, the Company’s disclosure controls and procedures as defined in Rules 13a-15(e) and 15d-15(e) under the Securities Exchange Act of 1934, as amended (the "Exchange Act") as of the end of the period covered by this report (the "Evaluation Date"). Based on such evaluation, the CEO and CFO have concluded that, as of the Evaluation Date, the Company’s disclosure controls and procedures are effective, at the reasonable assurance level, (a) in recording, processing, summarizing and reporting, on a timely basis, information required to be disclosed by the Company in the reports the Company files or submits under the Exchange Act, and (b) in assuring that information is accumulated and communicated to the Company’s management, including the CEO and CFO, as appropriate to allow timely decisions regarding required disclosure.

### Changes in Internal Control Over Financial Reporting

During the third quarter of fiscal 2022 there have been no changes in the Company’s internal control over financial reporting (as defined in Rules 13a-15(f) and 15d-15(f) under the Exchange Act) that have materially affected, or are reasonably likely to materially affect, the Company’s internal control over financial reporting.

## Risk factors

As filed, 403 characters.

In addition to the risks and uncertainties discussed herein, particularly those discussed in the “Safe Harbor” Cautionary Statement and "Management’s Discussion and Analysis of Financial Condition and Results of Operations" in Part I, Item 2, see the risk factors set forth in Part I, Item 1A of our Annual Report on Form 10-K for the fiscal year ended October 2, 2021 that have had no material changes.

Filed Aug 5, 2022.
Source: SEC EDGAR, the filing index for accession 0000785786-22-000073. Last ingested by Listed: Oct 24, 2026, 14:56 ET. No prices; not investment advice.
